nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—colon cancer	0.34	0.54	CbGaD
Lenalidomide—ABCB1—colon cancer	0.289	0.46	CbGaD
Lenalidomide—CDH5—endothelium—colon cancer	0.00974	0.101	CbGeAlD
Lenalidomide—CDH5—blood vessel—colon cancer	0.00898	0.0931	CbGeAlD
Lenalidomide—TNFSF11—embryo—colon cancer	0.00712	0.0738	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PTPRJ—colon cancer	0.0061	0.109	CbGpPWpGaD
Lenalidomide—CDH5—embryo—colon cancer	0.00536	0.0555	CbGeAlD
Lenalidomide—TNFSF11—lymphoid tissue—colon cancer	0.00447	0.0464	CbGeAlD
Lenalidomide—CDH5—epithelium—colon cancer	0.00437	0.0453	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—colon cancer	0.00421	0.0437	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—colon cancer	0.00407	0.0422	CbGeAlD
Lenalidomide—CRBN—embryo—colon cancer	0.0034	0.0353	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—colon cancer	0.00337	0.0349	CbGeAlD
Lenalidomide—CDH5—bone marrow—colon cancer	0.00307	0.0318	CbGeAlD
Lenalidomide—CDH5—vagina—colon cancer	0.00294	0.0304	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—BCL2L1—colon cancer	0.00259	0.0463	CbGpPWpGaD
Lenalidomide—CRBN—renal system—colon cancer	0.00258	0.0267	CbGeAlD
Lenalidomide—TNFSF11—lymph node—colon cancer	0.00252	0.0262	CbGeAlD
Lenalidomide—CDH5—liver—colon cancer	0.00248	0.0257	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—CDH1—colon cancer	0.00227	0.0406	CbGpPWpGaD
Lenalidomide—CRBN—lymphoid tissue—colon cancer	0.00214	0.0222	CbGeAlD
Lenalidomide—CRBN—digestive system—colon cancer	0.00211	0.0219	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—DCC—colon cancer	0.00202	0.0361	CbGpPWpGaD
Lenalidomide—CRBN—bone marrow—colon cancer	0.00195	0.0202	CbGeAlD
Lenalidomide—CDH5—lymph node—colon cancer	0.0019	0.0197	CbGeAlD
Lenalidomide—CRBN—vagina—colon cancer	0.00187	0.0193	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—colon cancer	0.00182	0.401	CrCbGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—colon cancer	0.00177	0.0317	CbGpPWpGaD
Lenalidomide—PTGS2—endothelium—colon cancer	0.00168	0.0175	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—colon cancer	0.00168	0.03	CbGpPWpGaD
Lenalidomide—CRBN—liver—colon cancer	0.00157	0.0163	CbGeAlD
Lenalidomide—PTGS2—blood vessel—colon cancer	0.00155	0.0161	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—colon cancer	0.00155	0.341	CrCbGaD
Lenalidomide—PTGS2—gall bladder—colon cancer	0.00146	0.0152	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—colon cancer	0.00134	0.0239	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CDH1—colon cancer	0.00131	0.0233	CbGpPWpGaD
Lenalidomide—CDH5—S1P2 pathway—PIK3CA—colon cancer	0.00129	0.0231	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—colon cancer	0.00125	0.0224	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—SRC—colon cancer	0.00123	0.022	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—colon cancer	0.00123	0.0219	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—colon cancer	0.00121	0.0216	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—colon cancer	0.00121	0.0125	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—colon cancer	0.00117	0.258	CrCbGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—PIK3CA—colon cancer	0.00106	0.019	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—colon cancer	0.000997	0.0178	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CDH1—colon cancer	0.000989	0.0177	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—colon cancer	0.000964	0.0172	CbGpPWpGaD
Lenalidomide—ABCB1—blood vessel—colon cancer	0.000961	0.00996	CbGeAlD
Lenalidomide—PTGS2—embryo—colon cancer	0.000926	0.00961	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—colon cancer	0.000872	0.0156	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—colon cancer	0.000869	0.0155	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—SRC—colon cancer	0.000789	0.0141	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—colon cancer	0.000768	0.0137	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—colon cancer	0.000766	0.0137	CbGpPWpGaD
Lenalidomide—PTGS2—epithelium—colon cancer	0.000756	0.00784	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—colon cancer	0.00073	0.013	CbGpPWpGaD
Lenalidomide—PTGS2—smooth muscle tissue—colon cancer	0.000728	0.00755	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—CDH1—colon cancer	0.000704	0.0126	CbGpPWpGaD
Lenalidomide—PTGS2—renal system—colon cancer	0.000701	0.00727	CbGeAlD
Lenalidomide—PTGS2—Overview of nanoparticle effects—BAX—colon cancer	0.000631	0.0113	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—colon cancer	0.000607	0.0108	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—colon cancer	0.0006	0.0107	CbGpPWpGaD
Lenalidomide—PTGS2—lymphoid tissue—colon cancer	0.000582	0.00604	CbGeAlD
Lenalidomide—PTGS2—digestive system—colon cancer	0.000575	0.00596	CbGeAlD
Lenalidomide—ABCB1—embryo—colon cancer	0.000573	0.00594	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—colon cancer	0.000573	0.0102	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—SRC—colon cancer	0.000549	0.0098	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—colon cancer	0.000534	0.00954	CbGpPWpGaD
Lenalidomide—PTGS2—bone marrow—colon cancer	0.00053	0.0055	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—colon cancer	0.000528	0.00943	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—colon cancer	0.000519	0.00928	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—SRC—colon cancer	0.000518	0.00925	CbGpPWpGaD
Lenalidomide—PTGS2—vagina—colon cancer	0.000508	0.00527	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—colon cancer	0.000504	0.00901	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—colon cancer	0.000498	0.0089	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—colon cancer	0.00049	0.00875	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DLC1—colon cancer	0.000488	0.00872	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—SRC—colon cancer	0.00047	0.00839	CbGpPWpGaD
Lenalidomide—ABCB1—epithelium—colon cancer	0.000468	0.00485	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—LGR5—colon cancer	0.000459	0.00819	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—colon cancer	0.000454	0.00811	CbGpPWpGaD
Lenalidomide—ABCB1—renal system—colon cancer	0.000434	0.0045	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—colon cancer	0.000429	0.00766	CbGpPWpGaD
Lenalidomide—PTGS2—liver—colon cancer	0.000428	0.00444	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PIK3CA—colon cancer	0.000417	0.00745	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PIK3CA—colon cancer	0.000394	0.00704	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—colon cancer	0.000386	0.0069	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—colon cancer	0.000365	0.00651	CbGpPWpGaD
Lenalidomide—ABCB1—lymphoid tissue—colon cancer	0.00036	0.00373	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—PIK3CA—colon cancer	0.000357	0.00638	CbGpPWpGaD
Lenalidomide—ABCB1—digestive system—colon cancer	0.000356	0.00369	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—colon cancer	0.000341	0.00609	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	0.00033	0.00589	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AXIN2—colon cancer	0.00033	0.00589	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—colon cancer	0.000329	0.00341	CbGeAlD
Lenalidomide—ABCB1—bone marrow—colon cancer	0.000328	0.0034	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—colon cancer	0.000322	0.00575	CbGpPWpGaD
Lenalidomide—ABCB1—vagina—colon cancer	0.000314	0.00326	CbGeAlD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000293	0.00524	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—colon cancer	0.000287	0.00513	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.00028	0.00499	CbGpPWpGaD
Lenalidomide—ABCB1—liver—colon cancer	0.000265	0.00275	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—colon cancer	0.000214	0.00382	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000208	0.00372	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000206	0.00369	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—colon cancer	0.000203	0.00211	CbGeAlD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.0002	0.00358	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000169	0.00301	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000157	0.00281	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	0.000156	0.00279	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.00015	0.00267	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000145	0.0026	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000142	0.00254	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000142	0.00253	CbGpPWpGaD
Lenalidomide—Bradycardia—Capecitabine—colon cancer	0.000141	0.000661	CcSEcCtD
Lenalidomide—Oedema—Fluorouracil—colon cancer	0.000141	0.00066	CcSEcCtD
Lenalidomide—Anorexia—Irinotecan—colon cancer	0.00014	0.000657	CcSEcCtD
Lenalidomide—Ataxia—Methotrexate—colon cancer	0.00014	0.000657	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.00014	0.0025	CbGpPWpGaD
Lenalidomide—Infection—Fluorouracil—colon cancer	0.00014	0.000656	CcSEcCtD
Lenalidomide—Haemoglobin—Capecitabine—colon cancer	0.000139	0.000652	CcSEcCtD
Lenalidomide—Rhinitis—Capecitabine—colon cancer	0.000139	0.000651	CcSEcCtD
Lenalidomide—Haemorrhage—Capecitabine—colon cancer	0.000138	0.000649	CcSEcCtD
Lenalidomide—Hepatitis—Capecitabine—colon cancer	0.000138	0.000649	CcSEcCtD
Lenalidomide—Nervous system disorder—Fluorouracil—colon cancer	0.000138	0.000647	CcSEcCtD
Lenalidomide—Thrombocytopenia—Fluorouracil—colon cancer	0.000138	0.000646	CcSEcCtD
Lenalidomide—Hypoaesthesia—Capecitabine—colon cancer	0.000138	0.000646	CcSEcCtD
Lenalidomide—Liver function test abnormal—Methotrexate—colon cancer	0.000137	0.000645	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000137	0.000645	CcSEcCtD
Lenalidomide—Pharyngitis—Capecitabine—colon cancer	0.000137	0.000644	CcSEcCtD
Lenalidomide—Tachycardia—Fluorouracil—colon cancer	0.000137	0.000644	CcSEcCtD
Lenalidomide—Hypotension—Irinotecan—colon cancer	0.000137	0.000644	CcSEcCtD
Lenalidomide—Urinary tract disorder—Capecitabine—colon cancer	0.000137	0.000641	CcSEcCtD
Lenalidomide—Insomnia—Vincristine—colon cancer	0.000136	0.00064	CcSEcCtD
Lenalidomide—Oedema peripheral—Capecitabine—colon cancer	0.000136	0.000639	CcSEcCtD
Lenalidomide—Connective tissue disorder—Capecitabine—colon cancer	0.000136	0.000638	CcSEcCtD
Lenalidomide—Urethral disorder—Capecitabine—colon cancer	0.000136	0.000636	CcSEcCtD
Lenalidomide—Paraesthesia—Vincristine—colon cancer	0.000135	0.000635	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000135	0.00241	CbGpPWpGaD
Lenalidomide—Breast disorder—Methotrexate—colon cancer	0.000135	0.000631	CcSEcCtD
Lenalidomide—Anorexia—Fluorouracil—colon cancer	0.000134	0.000629	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000134	0.000629	CcSEcCtD
Lenalidomide—Visual impairment—Capecitabine—colon cancer	0.000133	0.000625	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.000133	0.00238	CbGpPWpGaD
Lenalidomide—Insomnia—Irinotecan—colon cancer	0.000133	0.000623	CcSEcCtD
Lenalidomide—Paraesthesia—Irinotecan—colon cancer	0.000132	0.000619	CcSEcCtD
Lenalidomide—Hypotension—Fluorouracil—colon cancer	0.000131	0.000617	CcSEcCtD
Lenalidomide—Decreased appetite—Vincristine—colon cancer	0.000131	0.000615	CcSEcCtD
Lenalidomide—Dyspnoea—Irinotecan—colon cancer	0.000131	0.000614	CcSEcCtD
Lenalidomide—Erythema multiforme—Capecitabine—colon cancer	0.000131	0.000614	CcSEcCtD
Lenalidomide—Somnolence—Irinotecan—colon cancer	0.000131	0.000613	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.00013	0.00233	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Vincristine—colon cancer	0.00013	0.000611	CcSEcCtD
Lenalidomide—Fatigue—Vincristine—colon cancer	0.00013	0.00061	CcSEcCtD
Lenalidomide—Eye disorder—Capecitabine—colon cancer	0.000129	0.000607	CcSEcCtD
Lenalidomide—Dyspepsia—Irinotecan—colon cancer	0.000129	0.000606	CcSEcCtD
Lenalidomide—Tinnitus—Capecitabine—colon cancer	0.000129	0.000605	CcSEcCtD
Lenalidomide—Constipation—Vincristine—colon cancer	0.000129	0.000605	CcSEcCtD
Lenalidomide—Pain—Vincristine—colon cancer	0.000129	0.000605	CcSEcCtD
Lenalidomide—Asthma—Methotrexate—colon cancer	0.000129	0.000604	CcSEcCtD
Lenalidomide—Cardiac disorder—Capecitabine—colon cancer	0.000128	0.000602	CcSEcCtD
Lenalidomide—Flushing—Capecitabine—colon cancer	0.000128	0.000602	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000128	0.000601	CcSEcCtD
Lenalidomide—Decreased appetite—Irinotecan—colon cancer	0.000128	0.000599	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000127	0.00228	CbGpPWpGaD
Lenalidomide—Insomnia—Fluorouracil—colon cancer	0.000127	0.000597	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000127	0.000595	CcSEcCtD
Lenalidomide—Fatigue—Irinotecan—colon cancer	0.000127	0.000594	CcSEcCtD
Lenalidomide—Paraesthesia—Fluorouracil—colon cancer	0.000126	0.000593	CcSEcCtD
Lenalidomide—Pancreatitis—Methotrexate—colon cancer	0.000126	0.000592	CcSEcCtD
Lenalidomide—Pain—Irinotecan—colon cancer	0.000126	0.000589	CcSEcCtD
Lenalidomide—Constipation—Irinotecan—colon cancer	0.000126	0.000589	CcSEcCtD
Lenalidomide—Angiopathy—Capecitabine—colon cancer	0.000126	0.000589	CcSEcCtD
Lenalidomide—Dyspnoea—Fluorouracil—colon cancer	0.000125	0.000588	CcSEcCtD
Lenalidomide—Somnolence—Fluorouracil—colon cancer	0.000125	0.000587	CcSEcCtD
Lenalidomide—Immune system disorder—Capecitabine—colon cancer	0.000125	0.000586	CcSEcCtD
Lenalidomide—Mediastinal disorder—Capecitabine—colon cancer	0.000125	0.000585	CcSEcCtD
Lenalidomide—Chills—Capecitabine—colon cancer	0.000124	0.000582	CcSEcCtD
Lenalidomide—Dyspepsia—Fluorouracil—colon cancer	0.000124	0.000581	CcSEcCtD
Lenalidomide—Arrhythmia—Capecitabine—colon cancer	0.000124	0.00058	CcSEcCtD
Lenalidomide—Abdominal discomfort—Methotrexate—colon cancer	0.000123	0.000579	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Vincristine—colon cancer	0.000123	0.000579	CcSEcCtD
Lenalidomide—Decreased appetite—Fluorouracil—colon cancer	0.000122	0.000574	CcSEcCtD
Lenalidomide—Alopecia—Capecitabine—colon cancer	0.000122	0.000574	CcSEcCtD
Lenalidomide—Pancytopenia—Methotrexate—colon cancer	0.000122	0.000573	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—CA7—colon cancer	0.000122	0.00218	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000121	0.00057	CcSEcCtD
Lenalidomide—Mental disorder—Capecitabine—colon cancer	0.000121	0.000569	CcSEcCtD
Lenalidomide—Feeling abnormal—Irinotecan—colon cancer	0.000121	0.000568	CcSEcCtD
Lenalidomide—Erythema—Capecitabine—colon cancer	0.00012	0.000565	CcSEcCtD
Lenalidomide—Malnutrition—Capecitabine—colon cancer	0.00012	0.000565	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.00012	0.00215	CbGpPWpGaD
Lenalidomide—Neutropenia—Methotrexate—colon cancer	0.00012	0.000564	CcSEcCtD
Lenalidomide—Dysuria—Methotrexate—colon cancer	0.00012	0.000564	CcSEcCtD
Lenalidomide—Pain—Fluorouracil—colon cancer	0.00012	0.000564	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Irinotecan—colon cancer	0.00012	0.000563	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Methotrexate—colon cancer	0.00012	0.000561	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000119	0.00213	CbGpPWpGaD
Lenalidomide—Abdominal pain—Vincristine—colon cancer	0.000119	0.000559	CcSEcCtD
Lenalidomide—Body temperature increased—Vincristine—colon cancer	0.000119	0.000559	CcSEcCtD
Lenalidomide—Flatulence—Capecitabine—colon cancer	0.000119	0.000557	CcSEcCtD
Lenalidomide—Erectile dysfunction—Methotrexate—colon cancer	0.000119	0.000556	CcSEcCtD
Lenalidomide—Dysgeusia—Capecitabine—colon cancer	0.000118	0.000553	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Methotrexate—colon cancer	0.000117	0.000551	CcSEcCtD
Lenalidomide—Back pain—Capecitabine—colon cancer	0.000117	0.000547	CcSEcCtD
Lenalidomide—Abdominal pain—Irinotecan—colon cancer	0.000116	0.000545	CcSEcCtD
Lenalidomide—Body temperature increased—Irinotecan—colon cancer	0.000116	0.000545	CcSEcCtD
Lenalidomide—Feeling abnormal—Fluorouracil—colon cancer	0.000116	0.000544	CcSEcCtD
Lenalidomide—Muscle spasms—Capecitabine—colon cancer	0.000116	0.000543	CcSEcCtD
Lenalidomide—Pneumonia—Methotrexate—colon cancer	0.000115	0.000541	CcSEcCtD
Lenalidomide—Infestation NOS—Methotrexate—colon cancer	0.000115	0.000538	CcSEcCtD
Lenalidomide—Infestation—Methotrexate—colon cancer	0.000115	0.000538	CcSEcCtD
Lenalidomide—Depression—Methotrexate—colon cancer	0.000114	0.000537	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000114	0.000534	CcSEcCtD
Lenalidomide—Vision blurred—Capecitabine—colon cancer	0.000114	0.000532	CcSEcCtD
Lenalidomide—Tremor—Capecitabine—colon cancer	0.000113	0.000529	CcSEcCtD
Lenalidomide—Renal failure—Methotrexate—colon cancer	0.000113	0.000529	CcSEcCtD
Lenalidomide—Stomatitis—Methotrexate—colon cancer	0.000112	0.000525	CcSEcCtD
Lenalidomide—Ill-defined disorder—Capecitabine—colon cancer	0.000112	0.000524	CcSEcCtD
Lenalidomide—Urticaria—Fluorouracil—colon cancer	0.000112	0.000524	CcSEcCtD
Lenalidomide—Conjunctivitis—Methotrexate—colon cancer	0.000112	0.000523	CcSEcCtD
Lenalidomide—Anaemia—Capecitabine—colon cancer	0.000111	0.000522	CcSEcCtD
Lenalidomide—Body temperature increased—Fluorouracil—colon cancer	0.000111	0.000522	CcSEcCtD
Lenalidomide—Hypersensitivity—Vincristine—colon cancer	0.000111	0.000521	CcSEcCtD
Lenalidomide—Sweating—Methotrexate—colon cancer	0.00011	0.000516	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—colon cancer	0.000109	0.000513	CcSEcCtD
Lenalidomide—Malaise—Capecitabine—colon cancer	0.000109	0.00051	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—colon cancer	0.000109	0.000509	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—colon cancer	0.000108	0.000508	CcSEcCtD
Lenalidomide—Vertigo—Capecitabine—colon cancer	0.000108	0.000508	CcSEcCtD
Lenalidomide—Hypersensitivity—Irinotecan—colon cancer	0.000108	0.000508	CcSEcCtD
Lenalidomide—Asthenia—Vincristine—colon cancer	0.000108	0.000508	CcSEcCtD
Lenalidomide—Syncope—Capecitabine—colon cancer	0.000108	0.000507	CcSEcCtD
Lenalidomide—Leukopenia—Capecitabine—colon cancer	0.000108	0.000506	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—colon cancer	0.000107	0.000502	CcSEcCtD
Lenalidomide—Palpitations—Capecitabine—colon cancer	0.000106	0.000499	CcSEcCtD
Lenalidomide—Loss of consciousness—Capecitabine—colon cancer	0.000106	0.000497	CcSEcCtD
Lenalidomide—Asthenia—Irinotecan—colon cancer	0.000105	0.000494	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000105	0.00188	CbGpPWpGaD
Lenalidomide—Cough—Capecitabine—colon cancer	0.000105	0.000493	CcSEcCtD
Lenalidomide—Hypertension—Capecitabine—colon cancer	0.000104	0.000488	CcSEcCtD
Lenalidomide—Hypersensitivity—Fluorouracil—colon cancer	0.000104	0.000486	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—colon cancer	0.000104	0.000486	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000103	0.00185	CbGpPWpGaD
Lenalidomide—Diarrhoea—Vincristine—colon cancer	0.000103	0.000484	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—colon cancer	0.000103	0.000483	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—colon cancer	0.000103	0.000483	CcSEcCtD
Lenalidomide—Chest pain—Capecitabine—colon cancer	0.000103	0.000481	CcSEcCtD
Lenalidomide—Myalgia—Capecitabine—colon cancer	0.000103	0.000481	CcSEcCtD
Lenalidomide—Arthralgia—Capecitabine—colon cancer	0.000103	0.000481	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000102	0.00183	CbGpPWpGaD
Lenalidomide—Pharyngitis—Methotrexate—colon cancer	0.000102	0.00048	CcSEcCtD
Lenalidomide—Anxiety—Capecitabine—colon cancer	0.000102	0.000479	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000102	0.000478	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—colon cancer	0.000102	0.000477	CcSEcCtD
Lenalidomide—Discomfort—Capecitabine—colon cancer	0.000101	0.000475	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—colon cancer	0.000101	0.000474	CcSEcCtD
Lenalidomide—Diarrhoea—Irinotecan—colon cancer	0.0001	0.000471	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	0.0001	0.00179	CbGpPWpGaD
Lenalidomide—Dry mouth—Capecitabine—colon cancer	0.0001	0.00047	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—colon cancer	9.97e-05	0.000468	CcSEcCtD
Lenalidomide—Pruritus—Fluorouracil—colon cancer	9.95e-05	0.000467	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	9.95e-05	0.00178	CbGpPWpGaD
Lenalidomide—Visual impairment—Methotrexate—colon cancer	9.93e-05	0.000466	CcSEcCtD
Lenalidomide—Confusional state—Capecitabine—colon cancer	9.91e-05	0.000465	CcSEcCtD
Lenalidomide—Oedema—Capecitabine—colon cancer	9.83e-05	0.000461	CcSEcCtD
Lenalidomide—Infection—Capecitabine—colon cancer	9.77e-05	0.000458	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—colon cancer	9.74e-05	0.000457	CcSEcCtD
Lenalidomide—Dizziness—Irinotecan—colon cancer	9.71e-05	0.000456	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	9.71e-05	0.00173	CbGpPWpGaD
Lenalidomide—Shock—Capecitabine—colon cancer	9.67e-05	0.000454	CcSEcCtD
Lenalidomide—Nervous system disorder—Capecitabine—colon cancer	9.64e-05	0.000452	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—colon cancer	9.63e-05	0.000452	CcSEcCtD
Lenalidomide—Diarrhoea—Fluorouracil—colon cancer	9.62e-05	0.000451	CcSEcCtD
Lenalidomide—Thrombocytopenia—Capecitabine—colon cancer	9.62e-05	0.000451	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—colon cancer	9.6e-05	0.00045	CcSEcCtD
Lenalidomide—Tachycardia—Capecitabine—colon cancer	9.59e-05	0.00045	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—colon cancer	9.59e-05	0.00045	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—colon cancer	9.56e-05	0.000448	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	9.55e-05	0.00171	CbGpPWpGaD
Lenalidomide—Skin disorder—Capecitabine—colon cancer	9.55e-05	0.000448	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—FGFR3—colon cancer	9.52e-05	0.0017	CbGpPWpGaD
Lenalidomide—Rash—Vincristine—colon cancer	9.51e-05	0.000446	CcSEcCtD
Lenalidomide—Hyperhidrosis—Capecitabine—colon cancer	9.5e-05	0.000446	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—colon cancer	9.5e-05	0.000446	CcSEcCtD
Lenalidomide—Headache—Vincristine—colon cancer	9.45e-05	0.000443	CcSEcCtD
Lenalidomide—Anorexia—Capecitabine—colon cancer	9.37e-05	0.00044	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—colon cancer	9.35e-05	0.000438	CcSEcCtD
Lenalidomide—Vomiting—Irinotecan—colon cancer	9.34e-05	0.000438	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—colon cancer	9.3e-05	0.000436	CcSEcCtD
Lenalidomide—Dizziness—Fluorouracil—colon cancer	9.3e-05	0.000436	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—colon cancer	9.28e-05	0.000435	CcSEcCtD
Lenalidomide—Rash—Irinotecan—colon cancer	9.26e-05	0.000434	CcSEcCtD
Lenalidomide—Dermatitis—Irinotecan—colon cancer	9.25e-05	0.000434	CcSEcCtD
Lenalidomide—Chills—Methotrexate—colon cancer	9.24e-05	0.000434	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—EP300—colon cancer	9.24e-05	0.00165	CbGpPWpGaD
Lenalidomide—Headache—Irinotecan—colon cancer	9.2e-05	0.000432	CcSEcCtD
Lenalidomide—Hypotension—Capecitabine—colon cancer	9.19e-05	0.000431	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—colon cancer	9.1e-05	0.000427	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—colon cancer	9.02e-05	0.000423	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—colon cancer	8.97e-05	0.000421	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—colon cancer	8.97e-05	0.000421	CcSEcCtD
Lenalidomide—Nausea—Vincristine—colon cancer	8.96e-05	0.00042	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Capecitabine—colon cancer	8.96e-05	0.00042	CcSEcCtD
Lenalidomide—Vomiting—Fluorouracil—colon cancer	8.94e-05	0.00042	CcSEcCtD
Lenalidomide—Insomnia—Capecitabine—colon cancer	8.89e-05	0.000417	CcSEcCtD
Lenalidomide—Rash—Fluorouracil—colon cancer	8.87e-05	0.000416	CcSEcCtD
Lenalidomide—Dermatitis—Fluorouracil—colon cancer	8.86e-05	0.000416	CcSEcCtD
Lenalidomide—PTGS2—Disease—LGR5—colon cancer	8.84e-05	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CHST5—colon cancer	8.84e-05	0.00158	CbGpPWpGaD
Lenalidomide—Paraesthesia—Capecitabine—colon cancer	8.83e-05	0.000414	CcSEcCtD
Lenalidomide—Headache—Fluorouracil—colon cancer	8.81e-05	0.000413	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	8.78e-05	0.00157	CbGpPWpGaD
Lenalidomide—Dysgeusia—Methotrexate—colon cancer	8.78e-05	0.000412	CcSEcCtD
Lenalidomide—Dyspnoea—Capecitabine—colon cancer	8.76e-05	0.000411	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—APC—colon cancer	8.74e-05	0.00156	CbGpPWpGaD
Lenalidomide—Nausea—Irinotecan—colon cancer	8.72e-05	0.000409	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—colon cancer	8.67e-05	0.000407	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CA7—colon cancer	8.66e-05	0.00155	CbGpPWpGaD
Lenalidomide—Dyspepsia—Capecitabine—colon cancer	8.65e-05	0.000406	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	8.64e-05	0.00154	CbGpPWpGaD
Lenalidomide—Decreased appetite—Capecitabine—colon cancer	8.55e-05	0.000401	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Capecitabine—colon cancer	8.49e-05	0.000398	CcSEcCtD
Lenalidomide—Fatigue—Capecitabine—colon cancer	8.48e-05	0.000398	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—colon cancer	8.45e-05	0.000396	CcSEcCtD
Lenalidomide—Constipation—Capecitabine—colon cancer	8.41e-05	0.000394	CcSEcCtD
Lenalidomide—Pain—Capecitabine—colon cancer	8.41e-05	0.000394	CcSEcCtD
Lenalidomide—Nausea—Fluorouracil—colon cancer	8.36e-05	0.000392	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—colon cancer	8.32e-05	0.00039	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—colon cancer	8.29e-05	0.000389	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BRAF—colon cancer	8.22e-05	0.00147	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Capecitabine—colon cancer	8.1e-05	0.00038	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—colon cancer	8.09e-05	0.000379	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—colon cancer	8.06e-05	0.000378	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—colon cancer	8.05e-05	0.00144	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Capecitabine—colon cancer	8.04e-05	0.000377	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—colon cancer	8.03e-05	0.000376	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	7.94e-05	0.00142	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—colon cancer	7.86e-05	0.0014	CbGpPWpGaD
Lenalidomide—Cough—Methotrexate—colon cancer	7.82e-05	0.000367	CcSEcCtD
Lenalidomide—Urticaria—Capecitabine—colon cancer	7.81e-05	0.000366	CcSEcCtD
Lenalidomide—Abdominal pain—Capecitabine—colon cancer	7.77e-05	0.000365	CcSEcCtD
Lenalidomide—Body temperature increased—Capecitabine—colon cancer	7.77e-05	0.000365	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—colon cancer	7.68e-05	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—colon cancer	7.65e-05	0.00137	CbGpPWpGaD
Lenalidomide—Myalgia—Methotrexate—colon cancer	7.63e-05	0.000358	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—colon cancer	7.63e-05	0.000358	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—colon cancer	7.63e-05	0.000358	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	7.58e-05	0.00135	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	7.58e-05	0.000356	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—colon cancer	7.54e-05	0.000354	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	7.52e-05	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	7.44e-05	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ODC1—colon cancer	7.4e-05	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CHST5—colon cancer	7.4e-05	0.00132	CbGpPWpGaD
Lenalidomide—Confusional state—Methotrexate—colon cancer	7.38e-05	0.000346	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	7.32e-05	0.00131	CbGpPWpGaD
Lenalidomide—Infection—Methotrexate—colon cancer	7.27e-05	0.000341	CcSEcCtD
Lenalidomide—Hypersensitivity—Capecitabine—colon cancer	7.24e-05	0.00034	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—colon cancer	7.18e-05	0.000337	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—colon cancer	7.16e-05	0.000336	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—colon cancer	7.11e-05	0.000333	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—colon cancer	7.07e-05	0.000332	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	7.05e-05	0.00126	CbGpPWpGaD
Lenalidomide—Asthenia—Capecitabine—colon cancer	7.05e-05	0.000331	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—colon cancer	6.98e-05	0.000327	CcSEcCtD
Lenalidomide—Pruritus—Capecitabine—colon cancer	6.95e-05	0.000326	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—colon cancer	6.84e-05	0.000321	CcSEcCtD
Lenalidomide—Diarrhoea—Capecitabine—colon cancer	6.73e-05	0.000316	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—colon cancer	6.67e-05	0.000313	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—colon cancer	6.62e-05	0.00031	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—colon cancer	6.57e-05	0.000308	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—colon cancer	6.52e-05	0.000306	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—colon cancer	6.51e-05	0.00116	CbGpPWpGaD
Lenalidomide—Somnolence—Methotrexate—colon cancer	6.51e-05	0.000305	CcSEcCtD
Lenalidomide—Dizziness—Capecitabine—colon cancer	6.5e-05	0.000305	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—colon cancer	6.44e-05	0.000302	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—colon cancer	6.36e-05	0.000298	CcSEcCtD
Lenalidomide—PTGS2—Disease—AXIN2—colon cancer	6.35e-05	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	6.32e-05	0.00113	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Methotrexate—colon cancer	6.32e-05	0.000296	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—colon cancer	6.31e-05	0.000296	CcSEcCtD
Lenalidomide—Pain—Methotrexate—colon cancer	6.26e-05	0.000294	CcSEcCtD
Lenalidomide—Vomiting—Capecitabine—colon cancer	6.25e-05	0.000293	CcSEcCtD
Lenalidomide—Rash—Capecitabine—colon cancer	6.2e-05	0.000291	CcSEcCtD
Lenalidomide—Dermatitis—Capecitabine—colon cancer	6.19e-05	0.00029	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CASP3—colon cancer	6.16e-05	0.0011	CbGpPWpGaD
Lenalidomide—Headache—Capecitabine—colon cancer	6.16e-05	0.000289	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—colon cancer	6.13e-05	0.0011	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	6.12e-05	0.00109	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Methotrexate—colon cancer	6.03e-05	0.000283	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—colon cancer	6e-05	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—colon cancer	6e-05	0.00107	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Methotrexate—colon cancer	5.98e-05	0.000281	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—colon cancer	5.98e-05	0.00107	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—colon cancer	5.94e-05	0.00106	CbGpPWpGaD
Lenalidomide—Nausea—Capecitabine—colon cancer	5.84e-05	0.000274	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—colon cancer	5.81e-05	0.000273	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—colon cancer	5.8e-05	0.00104	CbGpPWpGaD
Lenalidomide—Body temperature increased—Methotrexate—colon cancer	5.78e-05	0.000271	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—colon cancer	5.78e-05	0.000271	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EP300—colon cancer	5.52e-05	0.000986	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—colon cancer	5.39e-05	0.000253	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	5.38e-05	0.00096	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SRC—colon cancer	5.37e-05	0.000959	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	5.34e-05	0.000954	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—colon cancer	5.25e-05	0.000246	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—ODC1—colon cancer	5.25e-05	0.000937	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CHST5—colon cancer	5.25e-05	0.000937	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—colon cancer	5.23e-05	0.000934	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	5.2e-05	0.000929	CbGpPWpGaD
Lenalidomide—Pruritus—Methotrexate—colon cancer	5.18e-05	0.000243	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRAS—colon cancer	5.16e-05	0.000922	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	5.15e-05	0.00092	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—colon cancer	5.04e-05	0.0009	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	5.03e-05	0.000899	CbGpPWpGaD
Lenalidomide—Diarrhoea—Methotrexate—colon cancer	5.01e-05	0.000235	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—colon cancer	4.84e-05	0.000227	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—colon cancer	4.81e-05	0.000859	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	4.8e-05	0.000857	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—colon cancer	4.8e-05	0.000857	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	4.79e-05	0.000855	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—colon cancer	4.7e-05	0.00084	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	4.66e-05	0.000832	CbGpPWpGaD
Lenalidomide—Vomiting—Methotrexate—colon cancer	4.65e-05	0.000218	CcSEcCtD
Lenalidomide—Rash—Methotrexate—colon cancer	4.61e-05	0.000216	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—colon cancer	4.61e-05	0.000216	CcSEcCtD
Lenalidomide—Headache—Methotrexate—colon cancer	4.58e-05	0.000215	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	4.54e-05	0.00081	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—colon cancer	4.44e-05	0.000794	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—colon cancer	4.35e-05	0.000204	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	4.17e-05	0.000745	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	4.16e-05	0.000743	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—colon cancer	4.08e-05	0.000729	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	4.08e-05	0.000729	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	4.08e-05	0.000729	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—colon cancer	3.95e-05	0.000705	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.86e-05	0.000689	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	3.79e-05	0.000677	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—colon cancer	3.78e-05	0.000675	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	3.69e-05	0.000659	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	3.65e-05	0.000652	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	3.57e-05	0.000637	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	3.54e-05	0.000633	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	3.43e-05	0.000612	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.39e-05	0.000606	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—colon cancer	3.34e-05	0.000596	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.3e-05	0.000589	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.21e-05	0.000574	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.06e-05	0.000546	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.96e-05	0.000528	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.95e-05	0.000527	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.89e-05	0.000517	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.89e-05	0.000517	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.73e-05	0.000488	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.51e-05	0.000448	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.43e-05	0.000434	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.05e-05	0.000366	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2e-05	0.000357	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—colon cancer	1.96e-05	0.000349	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—colon cancer	1.92e-05	0.000343	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR3—colon cancer	1.83e-05	0.000328	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—colon cancer	1.68e-05	0.000301	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—colon cancer	1.58e-05	0.000283	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.48e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—colon cancer	1.36e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—colon cancer	1.36e-05	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—colon cancer	1.14e-05	0.000204	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—colon cancer	1.12e-05	0.0002	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—colon cancer	1.06e-05	0.00019	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—colon cancer	1.03e-05	0.000185	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—colon cancer	9.95e-06	0.000178	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—colon cancer	9.65e-06	0.000172	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—colon cancer	9.27e-06	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—colon cancer	9.24e-06	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—colon cancer	9.06e-06	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—colon cancer	8.9e-06	0.000159	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—colon cancer	8.56e-06	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—colon cancer	7.87e-06	0.00014	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—colon cancer	7.59e-06	0.000136	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—colon cancer	7.28e-06	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—colon cancer	6.59e-06	0.000118	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—colon cancer	6.43e-06	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—colon cancer	6.31e-06	0.000113	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—colon cancer	5.38e-06	9.61e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—colon cancer	4.67e-06	8.34e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—colon cancer	3.81e-06	6.81e-05	CbGpPWpGaD
